Page last updated: 2024-12-06
victoria blue bo
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Victoria blue BO: a cationic triarylmethane dye; exhibits photodynamic activity against the human leukemic cell lines K-562 and TF-1 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 75444 |
CHEMBL ID | 3182706 |
SCHEMBL ID | 456095 |
SCHEMBL ID | 23596 |
MeSH ID | M0223714 |
Synonyms (72)
Synonym |
---|
victoria pure blue bod |
basic blue 7 |
c.i. basic blue 7 |
victoria pure blue rb |
victoria pure blue bgo |
brilliant victoria blue rs |
no. 3772 forthbrite blue b |
silosuper blue b |
nsc-51534 |
nsc51534 |
2390-60-5 |
brilliant victoria blue rb |
victoria pure blue bop |
victoria pure blue bon |
victoria blue, green shade |
victoria pure blue boc |
hidaco victoria blue bgo |
victoria pure blue bo ci 42595 |
victoria pure blue fbo |
victoria pure lake blue |
victoria pure lake blue bo |
victoria blue bon 110 |
aizen victoria pure blue boh |
victoria pure blue bo |
eljon blue toner |
victoria pure blue |
mitsui victoria pure blue bo |
calcozine pure blue bo |
victoria blue fbo |
sicilian blue x-2758 |
c.i. 42595 |
victoria blue bo |
aizen victoria blue bo |
victoria pure ink blue bo |
victoria pure blue bo, dye content 90 % |
ethanaminium, n-[4-[[4-(diethylamino)phenyl][4-(ethylamino)-1-naphthalenyl]methylene]-2,5-cyclohexadien-1-ylidene]-n-ethyl-, chloride |
n-(4-{[4-(diethylamino)phenyl][4-(ethylamino)naphthalen-1-yl]methylidene}cyclohexa-2,5-dien-1-ylidene)-n-ethylethanaminium chloride |
B1301 |
tox21_301536 |
NCGC00255579-01 |
dtxcid3018888 |
dtxsid5038888 , |
cas-2390-60-5 |
(4-(4-(diethylamino)-alpha-(4-(ethylamino)-1-naphthyl)benzylidene)cyclohexa-2,5-dien-1-ylidene)diethylammonium chloride |
n-(4-((4-(diethylamino)phenyl)(4-(ethylamino)-1-naphthalenyl)meth- ylene)-2,5-cyclohexadien-1-ylidene)-n-ethylethanaminium chloride |
einecs 219-232-0 |
unii-30f6f48h95 |
vb-bo |
ci 42595 |
nsc 51534 |
ethanaminium, n-(4-((4-(diethylamino)phenyl)(4-(ethylamino)-1-naphthalenyl)methylene)-2,5-cyclohexadien-1-ylidene)-n-ethyl-, chloride |
30f6f48h95 , |
ethanaminium, n-(4-((4-(diethylamino)phenyl)(4-(ethylamino)-1-naphthalenyl)methylene)-2,5-cyclohexadien-1-ylidene)-n-ethyl-, chloride (1:1) |
ethanaminium, n-(4-((4-(diethylamino)phenyl)(4-(ethylamino)-1-naphthalenyl)meth- ylene)-2,5-cyclohexadien-1-ylidene)-n-ethyl-, chloride |
FT-0622579 |
AKOS015901188 |
AKOS015903549 |
basic blue 7 [inci] |
aizen sbn blue 701 |
SCHEMBL456095 |
SCHEMBL23596 |
CHEMBL3182706 |
mfcd00011877 |
victoria pure blue bo, analytical standard |
J-015266 |
n-(4-((4-(diethylamino)phenyl)(4-(ethylamino)naphthalen-1-yl)methylene)cyclohexa-2,5-dienylidene)-n-ethylethanaminium chloride |
ROVRRJSRRSGUOL-UHFFFAOYSA-N |
Q421673 |
D88781 |
n-(4-((4-(diethylamino)phenyl)(4-(ethylamino)naphthalen-1-yl)methylene)cyclohexa-2,5-dien-1-ylidene)-n-ethylethanaminium chloride |
[4-[bis[4-(diethylamino)phenyl]methylidene]naphthalen-1-ylidene]-ethylazanium;chloride |
CAA39060 |
Research Excerpts
Overview
Victoria Blue BO (VB BO) is a new and promising photosensitizer currently being evaluated for photodynamic therapy (PDT)
Excerpt | Reference | Relevance |
---|---|---|
"Victoria Blue BO (VB BO) is a new and promising photosensitizer currently being evaluated for photodynamic therapy (PDT). " | ( Metabolic effects of photodynamically induced apoptosis in an erythroleukemic cell line. A (31)P NMR spectroscopic study of Victoria-Blue-BO-sensitized TF-1 cells. Chabannon, C; Cozzone, PJ; Julliard, M; Lutz, NW; Maroc, C; Viola, A, 2000) | 1.75 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (40)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 28.0963 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
acetylcholinesterase | Homo sapiens (human) | Potency | 40.8259 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 32.5605 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 2.4348 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 61.2754 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
SMAD family member 3 | Homo sapiens (human) | Potency | 61.2754 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.2257 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 13.7642 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063 |
caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 0.0342 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 96.2946 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 10.3826 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 28.7952 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 37.3204 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692; AID720719 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 3.7536 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 15.4097 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 0.2827 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 41.4791 | 0.3758 | 27.4851 | 61.6524 | AID743217; AID743220; AID743239 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 0.0242 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 14.5365 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 29.1502 | 0.0010 | 24.5048 | 61.6448 | AID743212; AID743215; AID743227 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 30.2018 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 19.7283 | 0.0237 | 23.2282 | 63.5986 | AID743222; AID743223; AID743241 |
caspase-3 | Homo sapiens (human) | Potency | 0.0342 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 0.8582 | 0.0007 | 23.0674 | 1,258.9301 | AID743122 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.2156 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 36.2362 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895; AID1259385; AID1259393; AID1259395 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 51.6423 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 7.5283 | 0.1549 | 17.8702 | 43.6557 | AID1346877 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 51.6423 | 19.7391 | 45.9784 | 64.9432 | AID1159509; AID1159518 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 11.0040 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 32.4978 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 0.1912 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 27.1395 | 0.0376 | 17.0823 | 61.1927 | AID1259364; AID1259388 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 12.8298 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 15.2617 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 0.6817 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 38.8418 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 0.6817 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 0.0858 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
Ataxin-2 | Homo sapiens (human) | Potency | 0.0858 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (141)
Molecular Functions (40)
Ceullar Components (27)
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (37.50) | 18.2507 |
2000's | 6 (37.50) | 29.6817 |
2010's | 2 (12.50) | 24.3611 |
2020's | 2 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 21.67
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.67) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (6.25%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (93.75%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |